Abstract
Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry in the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg virus (MARV) vaccines against aerosol challenge in cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against an aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6894-6900 |
| Number of pages | 7 |
| Journal | Vaccine |
| Volume | 26 |
| Issue number | 52 |
| DOIs | |
| State | Published - Dec 9 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Aerosol
- Ebola virus
- Filovirus
- Marburg virus
- Nonhuman primates
- Vaccines
ASJC Scopus subject areas
- Immunology and Microbiology(all)
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
- Molecular Medicine
Cite this
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. / Geisbert, Thomas; Daddario-DiCaprio, Kathleen M.; Geisbert, Joan B.; Reed, Douglas S.; Feldmann, Friederike; Grolla, Allen; Ströher, Ute; Fritz, Elizabeth A.; Hensley, Lisa E.; Jones, Steven M.; Feldmann, Heinz.
In: Vaccine, Vol. 26, No. 52, 09.12.2008, p. 6894-6900.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
AU - Geisbert, Thomas
AU - Daddario-DiCaprio, Kathleen M.
AU - Geisbert, Joan B.
AU - Reed, Douglas S.
AU - Feldmann, Friederike
AU - Grolla, Allen
AU - Ströher, Ute
AU - Fritz, Elizabeth A.
AU - Hensley, Lisa E.
AU - Jones, Steven M.
AU - Feldmann, Heinz
PY - 2008/12/9
Y1 - 2008/12/9
N2 - Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry in the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg virus (MARV) vaccines against aerosol challenge in cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against an aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection.
AB - Considerable progress has been made over the last decade in developing candidate preventive vaccines that can protect nonhuman primates against Ebola and Marburg viruses. A vaccine based on recombinant vesicular stomatitis virus (VSV) seems to be particularly robust as it can also confer protection when administered as a postexposure treatment. While filoviruses are not thought to be transmitted by aerosol in nature the inhalation route is among the most likely portals of entry in the setting of a bioterrorist event. At present, all candidate filoviral vaccines have been evaluated against parenteral challenges but none have been tested against an aerosol exposure. Here, we evaluated our recombinant VSV-based Zaire ebolavirus (ZEBOV) and Marburg virus (MARV) vaccines against aerosol challenge in cynomolgus macaques. All monkeys vaccinated with a VSV vector expressing the glycoprotein of ZEBOV were completely protected against an aerosol exposure of ZEBOV. Likewise, all monkeys vaccinated with a VSV vector expressing the glycoprotein of MARV were completely protected against an aerosol exposure of MARV. All control animals challenged by the aerosol route with either ZEBOV or MARV succumbed. Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection.
KW - Aerosol
KW - Ebola virus
KW - Filovirus
KW - Marburg virus
KW - Nonhuman primates
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=56649099057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649099057&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2008.09.082
DO - 10.1016/j.vaccine.2008.09.082
M3 - Article
C2 - 18930776
AN - SCOPUS:56649099057
VL - 26
SP - 6894
EP - 6900
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 52
ER -